Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iopanoic acid is an iodine-containing small molecule radiocontrast agent formerly used in cholecystography. It acts as a potent inhibitor of thyroid hormone release from the thyroid gland and inhibits the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) by blocking thyroxine 5'-deiodinase enzymes. This mechanism makes it effective for rapid control of hyperthyroidism, particularly in severe cases or when standard antithyroid therapies are ineffective or contraindicated. Iopanoic acid has also been used as adjunctive therapy before thyroidectomy and in neonatal thyrotoxicosis. Its use for treating thyrotoxicosis has been discontinued in several countries, including the United States[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iopanoic acid.